PASG News and Press, Passage Bio Inc. From 04/11/22

Not long ago, PASG was awarded a $1.2B enterprise value by the market. Though the company made progress, the vagaries of the market are such that it now trades at a negative enterprise value. I survey the company and its programs to find reasons to monitor its progress with the po...

Preclinical studies conducted with University of Pennsylvania’s Gene Therapy Program demonstrate biologic effects of vector-optimized gene therapy PBKR03 for Krabbe disease PBKR03 showed marked improvements in safety, disease progression and key biomarkers for Krabbe disease in...

PHILADELPHIA, March 28, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that management will participate in the following upcoming...

Passage Bio (NASDAQ:PASG) is reducing its workforce by ~13% and prioritizing research and development programs to reduce operating expenses. The company said it is prioritizing its R&D programs in partnership with the University of Pennsylvania’s Gene Therapy Program (GTP). Th...

Company to reduce workforce and prioritize research and development programs to reduce operating expenses Continued focus on execution of three ongoing clinical trials for GM1 gangliosidosis, Krabbe disease and frontotemporal dementia Estimated cash runway extended int...

PHILADELPHIA, March 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, announced that the first patient with early infantile Krabbe disease has r...

Palm Beach, FL –– March 8, 2022 – FinancialNewsMedia.com News Commentary – According to a report from Grand View Research “High unmet medical needs and government initiatives to reduce the psychiatric and neurological disorders are driving the ...

The following slide deck was published by Passage Bio, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Passage Bio, Inc. 2021 Q4 - Results - Earnings Call Presentation

Passage Bio, Inc. (PASG) Q4 2021 Earnings Conference Call March 3, 2022 08:30 AM ET Company Participants Stuart Henderson - VP, IR and Strategic Finance Bruce Goldsmith - President and CEO Eliseo Salinas - Chief Research and Development Officer Simona King - CFO Conference Call Participants T...

Passage Bio press release (NASDAQ:PASG): Q4 GAAP EPS of -$0.95 misses by $0.06. Q4 cash equivalents $315.8M For further details see: Passage Bio GAAP EPS of -$0.95 misses by $0.06